**PGN-600** is a [[Tofacitinib|tofacitinib]] liquid formulation delivered via [[DDS|DDS]] capsule, developed by [[Biora Therapeutics]]. Considered a [[Combination Products|drug device combination]]. Expected to treat [[Ulcerative Colitis|ulcerative colitis]] as part of the [[Targeted Therapeutics Pipeline|Targeted Therapeutics Pipeline]]. > [!quote] PGN-600: Liquid formulation of tofacitinib delivered with the DDS for the treatment of ulcerative colitis > We are developing PGN-600 as an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis. Tofacitinib is approved for ulcerative colitis and is dose limited based on safety concerns, making it an ideal therapy for targeted delivery. > > Our preclinical data demonstrates that targeted delivery using PGN-600 can lead to reduced drug levels in blood and to increased levels in tissue at least 25 times higher along the length of the colon versus the equivalent standard oral dose.  > > If we demonstrate similar results clinically to what has been observed preclinically, and given the known efficacy of the currently approved doses of tofacitinib, we believe PGN-600 has the potential to greatly improve patient outcomes in ulcerative colitis. > > Source: <https://www.bioratherapeutics.com/pipeline/targeted-therapeutics>